Drugmaker Bristol Myers Squibb said on Friday the U.S. Food and Drug Administration (FDA) has extended the review of its drug candidate, mavacamten, for the treatment of a heart condition. Read More
Categories
Bristol Myers Says U.S. FDA Extends Review of Heart Disease Drug
